Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Linrodostat + nivolumab ± ipilimumab demonstrated a manageable safety profile. Kynurenine changes supported indoleamine 2,3-dioxygenase 1 pathway inhibition but did not correlate with response. A composite biomarker of low tryptophan 2,3-dioxygenase expression plus high IFN-γ gene expression may predict response to linrodostat + nivolumab. See related commentary by Zang and Dorff, p. 2077.
Authors
- Lillian L. Siu (ORCID: https://orcid.org/0000-0002-3500-0540)
- Carlos Gomez‐Roca (ORCID: https://orcid.org/0000-0002-8043-2529)
- Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
- Víctor Moreno (ORCID: https://orcid.org/0000-0001-6099-4236)
- Josep M. Tabernero (ORCID: https://orcid.org/0000-0002-2495-8139)
- Rasha Cosman (ORCID: https://orcid.org/0000-0002-4746-0747)
- Julia Santucci-Pereira (ORCID: https://orcid.org/0000-0003-4958-1128)
- Lily Wang
- Chandrika Jeyamohan
- Rachel Tam (ORCID: https://orcid.org/0009-0009-8556-1109)
- Xianling Wang (ORCID: https://orcid.org/0000-0002-3484-1671)
- Jason J. Luke (ORCID: https://orcid.org/0000-0002-1182-4908)
- Karen A. Gelmon (ORCID: https://orcid.org/0000-0003-4111-2757)
- Silvia Damian (ORCID: https://orcid.org/0000-0001-9560-1092)
- Jayesh Desai (ORCID: https://orcid.org/0000-0003-4246-9344)
- Quincy S. Chu (ORCID: https://orcid.org/0000-0003-4814-3126)
- Russell K. Pachynski (ORCID: https://orcid.org/0000-0002-8966-7631)
- Matteo Salvatore Carlino (ORCID: https://orcid.org/0000-0002-7861-4104)
- Li Zhu (ORCID: https://orcid.org/0000-0002-8804-4897)
- Danielle Greenawalt (ORCID: https://orcid.org/0000-0002-6297-0753)
Institutions
- Universitat de Vic - Universitat Central de Catalunya (ES)
- BC Cancer Agency (CA)
- University Health Network (CA)
- Garvan Institute of Medical Research (AU)
- University of British Columbia (CA)
- University of Alberta (CA)
- The University of Melbourne (AU)
- University of Pittsburgh (US)
- University of Milan (IT)
- Washington University in St. Louis (US)
- Peter MacCallum Cancer Centre (AU)
- Princess Margaret Cancer Centre (CA)
- Westmead Hospital (AU)
- St Vincent's Hospital Sydney (AU)
- Bristol-Myers Squibb (United States) (US)
- Instituto Oncológico Dr. Rosell (ES)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Melanoma Institute Australia (AU)
- Institut Claudius Regaud (FR)
- Hospital Universitario Fundación Jiménez Díaz (ES)
- Bristol-Myers Squibb (Sweden) (SE)
- The Kinghorn Cancer Centre (AU)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- European Institute of Oncology (IT)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-12-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-0439
- Citations
- 12
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.89